Captrust Financial Advisors Raises Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Captrust Financial Advisors raised its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 22.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 28,152 shares of the medical device company's stock after purchasing an additional 5,101 shares during the period. Captrust Financial Advisors' holdings in DexCom were worth $2,189,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in DXCM. Congress Asset Management Co. lifted its position in DexCom by 5,456.9% during the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock valued at $105,529,000 after purchasing an additional 1,332,522 shares during the last quarter. Janney Montgomery Scott LLC lifted its holdings in shares of DexCom by 2,226.6% in the 4th quarter. Janney Montgomery Scott LLC now owns 232,543 shares of the medical device company's stock valued at $18,085,000 after acquiring an additional 222,548 shares during the last quarter. Proficio Capital Partners LLC purchased a new position in DexCom in the fourth quarter worth about $5,812,000. Mitsubishi UFJ Asset Management UK Ltd. increased its stake in DexCom by 500.0% during the fourth quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 6,000 shares of the medical device company's stock worth $467,000 after acquiring an additional 5,000 shares during the last quarter. Finally, Merit Financial Group LLC purchased a new stake in DexCom during the fourth quarter valued at approximately $228,000. Hedge funds and other institutional investors own 97.75% of the company's stock.

DexCom Trading Down 0.2%

Shares of DexCom stock traded down $0.19 on Friday, hitting $85.48. 3,397,377 shares of the company traded hands, compared to its average volume of 4,347,202. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The company has a market cap of $33.52 billion, a PE ratio of 59.78, a PEG ratio of 2.30 and a beta of 1.43. The stock's 50 day moving average price is $71.70 and its 200-day moving average price is $77.51. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $132.26.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). The firm had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. The business's quarterly revenue was up 12.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.32 EPS. Equities research analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Barclays lifted their target price on DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a report on Monday, May 5th. Cfra Research raised shares of DexCom to a "hold" rating in a research note on Friday, March 21st. Citigroup boosted their price objective on shares of DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a research report on Tuesday, March 4th. Morgan Stanley raised their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a report on Friday, February 14th. Finally, Baird R W raised shares of DexCom from a "hold" rating to a "strong-buy" rating in a research note on Thursday, January 16th. Five research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, DexCom has an average rating of "Moderate Buy" and a consensus target price of $98.11.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Michael Jon Brown sold 13,000 shares of the company's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $914,940.00. Following the completion of the sale, the executive vice president now owns 105,602 shares in the company, valued at $7,432,268.76. This represents a 10.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Jereme M. Sylvain sold 7,000 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $73.83, for a total value of $516,810.00. Following the sale, the executive vice president now directly owns 135,482 shares in the company, valued at $10,002,636.06. This trade represents a 4.91% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 66,926 shares of company stock valued at $4,734,384. Company insiders own 0.32% of the company's stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.